References
1. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987 Jul;7(4):294–9.
2. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011 Jun;127(6):1329-1341.e2; quiz 1342–3.
3. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796–801.
4. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010 Aug 26;116(8):1228–34.
5. Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. Am J Hematol. 2011 Jan;86(1):48–55.
6. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008 Sep;22(5):261–81.
7. Mellemkjaer L, Hammarström L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130(3):495–500.
8. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008 May 15;46(10):1547–54.
9. Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematol Am Soc Hematol Educ Program. 2012;2012:301–5.
10. CEREDIH: The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol Orlando Fla. 2010 May;135(2):264–72.
11. Picard C, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015 Nov;35(8):696–726.
12. Chan H-Y, Yang Y-H, Yu H-H, Chien Y-H, Chiang L-L, Chiang B-L. Clinical characteristics and outcomes of primary antibody deficiency: a 20-year follow-up study. J Formos Med Assoc Taiwan Yi Zhi. 2014 Jun;113(6):340–8.
13. Dabaja BS, Advani R, Hodgson DC, Dhakal S, Flowers CR, Ha CS, et al. ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma: Am J Clin Oncol. 2015 Dec;38(6):610–20.
14. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Cancer Netw JNCCN. 2016;14(9):1067–79.
15. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26:v116–25.
16. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009 May;50(5):764–72.
17. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach: When to initiate IgG therapy in antibody deficiency. Clin Exp Immunol. 2017 Jun;188(3):333–41.
18. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol [Internet]. 2019 Feb 8 [cited 2020 Aug 24];10. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2019.00033/full
19. Benbrahim O, Viallard J-F, Choquet S, Royer B, Bauduer F, Decaux O, et al. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. Eur J Haematol. 2018 Jul;101(1):48–56.
20. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019 Aug;7(6):1763–70.
21. Ameratunga R, Woon S-T, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013 Nov;174(2):203–11.
22. Ameratunga R, Woon S-T. Perspective: Evolving Concepts in the Diagnosis and Understanding of Common Variable Immunodeficiency Disorders (CVID). Clin Rev Allergy Immunol. 2020 Aug;59(1):109–21.
23. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016 Oct;101(10):1244–50.
24. Desandes E, Lacour B, Clavel J, le Réseau français des registres de cancers. [Cancer in adolescents and young adults in France: Epidemiology and pathways of care]. Bull Cancer (Paris). 2016 Dec;103(12):957–65.
25. Mahlaoui N, Picard C, Bach P, Costes L, Courteille V, Ranohavimparany A, et al. Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry. J Allergy Clin Immunol. 2019 Apr;143(4):1646-1649.e10.